Investing Center Preview – Manage your investments and watch your net worth grow.
ALPMY:Grey Market – Large Cap Stock ()
Astellas Pharma Inc – ALPMY Stock Overview
Last Price | Today's Change | 52-Week Range | Trading Volume |
---|---|---|---|
9.70 | -0.03 (-0.31%) | 9.05 - 13.14 | 949.0 (Above Avg) |
Market data as of 9:30AM 04/02/25. Quotes are delayed by at least 15 min.
Overview - ALPMY
Open | 9.70 |
---|---|
Previous Close | 9.73 |
Day's Range | 9.70 - 9.70 |
Market Cap | 17.6B |
Avg Volume (10 Day) | 89.0K |
Price/Earnings (Trailing 12 Mo.) | -- |
Earnings Per Share (Trailing 12 Mo.) | 19.551 |
Dividend Yield | 0.2467 (4.85%) |
One-Click Scorecard - ALPMY


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Performed well consistently? | Neutral |
---|---|
Avoids excess debt? | Neutral |
Converting sales to profits? | Neutral |
Shareholder's money handled rationally? | Neutral |
Increased shareholder value? | Neutral |
Consistently increased owner earnings? | Neutral |
Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Pays a cash dividend? | Neutral |
---|---|
Room to increase dividends? | Neutral |
Increased earnings over time? | Neutral |
Borrows within reasonable limits? | Neutral |
Stock is undervalued? | Neutral |
Have investors caught on? | Neutral |
Has support of institutional investors? | Neutral |
Has sufficient liquidity? | Neutral |
Latest Headlines - ALPMY
Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing
PR Newswire - Wednesday 03/05/2025 11:02 PM ET
Industry Position - ALPMY
ALPMY | Industry Range | |
---|---|---|
Revenue Growth (1yr) | 5.60% | |
Net Income Growth (1yr) | -82.73% | |
Total Debt/Equity | 0.61 | |
LT Debt/Equity | 0.41 | |
Earnings Yield | -- | |
Price/Sales | 1.39 |
Competitors - ALPMY
Company | Last | Change |
---|
Data is delayed by at least 15 min.